Attorney's Docket No.: 17083-003002 / 1227B



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ficant: Carlos F. Barbas III et al.

Art Unit : 1646

Serial No.: 09/586,625

Examiner: Joseph F. Murphy

Filed

: June 2, 2000

Cust. No. : 20985

Conf. No.: 6568

Title

: LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Forms PTO-1449 (3) pages, cited non U.S. patent references, and a check in the amount of \$180.00 for filing in connection with the above-identified application.

The Commissioner is hereby authorized to charge any fees that may be due in connection with this paper or with this application during its entire pendency to Deposit Account No. 06-1050. A duplicate of this sheet is enclosed.

Respectfully submitted,

Stephanie Seidman Reg. No. 33,779

Attorney Docket No. 17083-003002/1227B

Address all correspondence to:

Stephanie L. Seidman

Fish & Richardson P.C.

12390 El Camino Real

San Diego, California 92130

Telephone: (858) 678-5070 Facsimile: (202) 626-7796

email: seidman@fr.com

CERTIFICATE OF MAILING BY EXPRESS MAIL" "Express Mail" Mailing Label Number EV/471536946 US

Date of Deposit November 22, 2005

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 CFR §1.10 on the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie Seidman

Attorney's Docket No.: 17083-003002/1227B

TATES PATENT AND TRADEMARK OFFICE

Carlos F. Barbas III et al. Art Unit : 1646

Serial No. 09/586,625 Examiner: Joseph F. Murphy

June 2, 2000 Filed Cust. No. : 20985

Conf. No.: 6568

: LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS Title

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Because this Supplemental Information Disclosure Statement is filed after the receipt of a First Office Action on the Merits for the above-captioned application, a check for the filing fee of \$180.00 is enclosed. If no proper payment is enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1050.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (2 pages) and copies of the cited non U.S. Patent documents are provided herewith.

The documents cited on the Forms PTO-1449 are in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

The above-captioned application designates three inventors, Carlos F. Barbas, III, Roger Beerli and Michael J. Kadan, and ultimately two assignees, Novartis AG, and The

11/28/2005 CNGUYEN 00000046 09586625

180.00 OP 01 FC:1806

CERTIFICATE OF MAILING BY "EXPRESS MAIL" "Express Mail" Mailing Label Number EV 471536946 US

Date of Deposit November 22, 2005

I hereby certify that this paper is being deposited with the United States Postal "Express Mail/Post Office to Addressee" Service under 37 CFR §1.10 on/the date indicated above and is addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA, 22313-1450.

Stephanie L. Seidman

Applicant: Carlos F. Barbas III et al. Attorney's Docket No.: 17083-003002 /1227B

Serial No. : 09/586,625 Filed : June 2, 2000 Page : 2 of 2

Scripps Research Institute. Michael J. Kadan assigned to Novartis AG. Carlos F. Barbas, III and Roger Beerli assigned to The Scripps Research Institute. Thus, the above-captioned application has joint inventors and two assignees.

Applicant also makes known to the Examiner the following pending U.S. Applications that have one or more common inventors and/or are commonly owned:

U.S.S.N.(App. No.)	Filing Date
10/157,899	05/31/02
10/487,268	06/18/04
10/941,069	09/14/04
10/646,919	08/21/03

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and they be made of record in the file history of the above-captioned/application:

Respectfully submitted,

Stephanie Seidman Reg. No. 33,779

Attorney Docket No. 17083-003002/1227B

Address all correspondence to:
Stephanie L. Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130

Telephone: (858) 678-5070 Facsimile: (202) 626-7796 email: seidman@fr.com

08/21/03

02/09/00

Department of Commerce atent and Trademark Office Substitute Form PTO-1449 Application No. Attorney's Docket No. (Modified) 17083-003002/1227B 09/586,625 Applicant Carlos F. Barbas III et al. List of Patents and Publications for Applicant's **Information Disclosure Statement** Group Art Unit Filing Date 1646 June 2, 2000 (37 CFR §1.98(b)) **U.S. Patent Documents** Examiner Desig. Document Publication Filing Date Initial ID Number Date Subclass If Appropriate Patentee Class 2003/0143559 07/31/03 705 1 03/27/01 AASansone, R.P. AB2003/0186841 10/02/03 Barbas III et al. 514 1 04/23/03 69.1 AC2004/0224385 04/21/05 435 06/18/04 Barbas et al. 2005/0084885 04/11/05 Barbas, III et al. 435 6 09/14/04 AD

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document	Publication	Country or				lation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AG	01/52620	07/26/01	PCT				
	AH	02/06463	01/24/02	PCT				
	AI	2002/097050	12/05/02	PCT				

Barbas, C.F.

Barbas III et al.

435

530

455

400

AE

AF

2005/0148075

6,790,941

07/07/05

09/14/04

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
	AJ	Alwin et al., "Custom zinc-finger nucleases for use in human cells," Mol. Ther. 12(4): 610-617 (2005)		
	AK	Beerli, R.R.and C.F. Barbas III, "Engineering polydactyl zinc-finger transcription factors," Nature Biotechnology 20(2): 135-41 (2002)		
	AL	Blancafort et al., "Designing transcription factor architectures for drug discovery," Mol. Pharmacol. 66(6): 1361-71 (2004)		
	AM	Blancafort et al., "Genetic reprogramming of tumor cells by zinc finger transcription factors," Proc. Natl. Acad. Sci. USA 102(33): 11716-21 (2005)		
	AN	Blancafort et al., "Scanning the human genome with combinatorial transcription factor libraries," Nature Biotechnol. 31(3): 269-274 (2003)		
	AO	Blau et al., "γ-globin gene expression in CID-dependent multi-potential cells established from beta YAC transgenic mice," J. Biol. Chem. August 30, 2005		
	AP	Dreier et al., "Development of zinc finger domains for recognition of the 5'-ANN-3' family of DNA sequences and their use in the construction of artificial transcription factors," J. Biol. Chem. 276(31): 29466-78 (2001)		
	AQ	Dreier et al., "Development of zinc finger domains for recognition of the 5'-CNN-3' family DNA sequences and their use in the construction of artificial transcription factors," J. Biol. Chem. 280(42):35588-35597 (2005)		

Examiner Signature	Date Considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in				
conformance and not considered. Include copy of this form with next co	mmunication to applicant.			

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17083-003002/1227B	Application No. 09/586,625	
List of Patents and Pu	blications for Applicant's	Applicant Carlos F. Barbas III et al.		
Information Disclosure Statement		Filing Date June 2, 2000	Group Art Unit 1646	
(37 CFR §1.98(b))				

<u> </u>	Other D	ocuments (include Author, Title, Date, and Place of Publication)		
Examiner	Desig.			
Initial	ID	Document		
		Graslund et al., "Exploring strategies for the design of artificial transcription factors: targeting sites		
AR		proximal to known regulatory regions for the induction of γ-globin expression and the treatment of		
		sickle cell disease," J. Biol. Chem. 280(5): 3707-14 (2005)		
	AS	Guan et al., "Heritable endogenous gene regulation in plants with designed polydactyl zinc finger		
	1.0	transcription factors," Proc. Natl. Acad. Sci. USA 99(20): 13296-301 (2002)		
	AT	Lin et al., "Small-molecule switches for zinc finger transcription factors," J. Am Chem. Soc. 125(3):		
		612-3 (2003)		
	AU	Lund et al., "Promoter-targeted phage display selections with preassembled synthetic zinc finger		
		libraries for endogenous gene regulation," J. Mol. Biol. 340(3): 599-613 (2004)		
	AV	Lund et al., "Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErB2 and		
		ErbB3 Receptors: Insights into ErbB Receptor Biology," Mol. Cell. Biol. 25(20): 9082-91 (2005)		
		Magnenat et al., "In vivo selection of combinatorial libraries and designed affinity maturation of		
	AW	polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation,"		
	ļ	J. Mol. Biol. 341(3): 635-49 (2004)		
	AX	Ordiz et al., "Regulation of transgene expression in plants with polydactyl zinc finger transcription		
		factors," Proc. Natl. Acad. Sci. USA 99(20): 13290-5 (2002)		
	AY	Segal et al., "Custom DNA-binding proteins come of age: polydactyl zinc-finger proteins," Curr. Opin. Biotechnol. 12(6): 632-7 (2001)		
		Segal et al., "Evaluation of a modular strategy for the construction of novel polydactyl zinc finger		
	AZ	DNA-binding proteins," Biochemistry 42(7): 2137-2148 (2003)		
		Segal et al., "Attenuation of HIV-1 replication in primary human cells with a designed zinc finger		
	BA	transcription factor," J. Biol. Chem. 279(15): 14509-19 (2004)		
		Segal et all., "Zinc fingers and a green thumb: manipulating gene expression in plants," Curr. Opin.		
	BB	Plant Biol. 6(2): 163-8 (2003)		
Stege et al "Controlling gene evn		Stege et al., "Controlling gene expression in plants using synthetic zinc finger transcription factors,"		
	BC	Plant J. 32(6): 1077-86 (2002)		
<u>-</u>		Tan et al., "Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the		
	BD	designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites," J.		
		Virol. 78(3): 1301-13 (2004)		
	D.F.	Xu et al., "A versatile framework for the design of ligand-dependent, transgene-specific		
	BE	transcription factors," Mol. Ther. 3(2): 262-73 (2001)		

Examiner Signature	Date Considered